Barrie Wilkinson
Founder at Isomerase Therapeutics Ltd.
Profile
Barrie Wilkinson is the founder and Non-Executive Director at Isomerase Therapeutics Ltd.
founded in 2012.
He was also a Vice President-Research at Biotica Technology Ltd.
from 2001 to 2013.
Dr. Wilkinson received his undergraduate degree in 1990 and his doctorate in 1993 from the University of Leeds.
Barrie Wilkinson active positions
| Companies | Position | Start |
|---|---|---|
Isomerase Therapeutics Ltd.
 Isomerase Therapeutics Ltd. BiotechnologyHealth Technology Isomerase Therapeutics Ltd. operates as a drug discovery and development company. It specializes in biosynthetic medicinal chemistry and synthetic biology, microbial natural products, microbial natural products, and semisynthetic chemistry. The company was founded by Barrie Wilkinson, Matthew Gregory, and Steven Moss in 2012 and is headquartered in Cambridge, the United Kingdom. | Founder | 2011-12-31 |
Former positions of Barrie Wilkinson
| Companies | Position | End |
|---|---|---|
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB. | Chief Tech/Sci/R&D Officer | 2013-03-11 |
Training of Barrie Wilkinson
| University of Leeds | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Biotica Technology Ltd.
Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB. | Health Technology |
Isomerase Therapeutics Ltd.
Isomerase Therapeutics Ltd. BiotechnologyHealth Technology Isomerase Therapeutics Ltd. operates as a drug discovery and development company. It specializes in biosynthetic medicinal chemistry and synthetic biology, microbial natural products, microbial natural products, and semisynthetic chemistry. The company was founded by Barrie Wilkinson, Matthew Gregory, and Steven Moss in 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Barrie Wilkinson
